These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35986867)

  • 101. Flaws in Anticoagulation Strategies in Patients With Atrial Fibrillation at Hospital Discharge.
    Kartas A; Samaras A; Vasdeki D; Dividis G; Fotos G; Paschou E; Forozidou E; Tsoukra P; Kotsi E; Goulas I; Efthimiadis G; Karvounis H; Tzikas A; Giannakoulas G
    J Cardiovasc Pharmacol Ther; 2019 May; 24(3):225-232. PubMed ID: 30599759
    [TBL] [Abstract][Full Text] [Related]  

  • 102. Occurrence of Ischemic Stroke in Patients With Atrial Fibrillation Receiving Non-Vitamin K Oral Anticoagulants: Causes and Prevention Strategies.
    Bang OY; Park KM; Jeong DS
    J Stroke; 2023 May; 25(2):199-213. PubMed ID: 36916018
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Impact of minor bleeds on confidence in anticoagulation therapy, adherence to treatment and quality of life in patients using a non-vitamin K antagonist oral anticoagulant for atrial fibrillation.
    Mitrovic D; Veeger N; van Roon E
    Curr Med Res Opin; 2022 Sep; 38(9):1485-1488. PubMed ID: 35656940
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Epidemiology and impact of frailty in patients with atrial fibrillation in Europe.
    Proietti M; Romiti GF; Vitolo M; Harrison SL; Lane DA; Fauchier L; Marin F; Näbauer M; Potpara TS; Dan GA; Maggioni AP; Cesari M; Boriani G; Lip GYH;
    Age Ageing; 2022 Aug; 51(8):. PubMed ID: 35997262
    [TBL] [Abstract][Full Text] [Related]  

  • 105. In AF, underdosing of DOACs was not linked to reduced bleeding.
    Dunn A
    Ann Intern Med; 2023 Mar; 176(3):JC32. PubMed ID: 36877969
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Perceived vs. objective frailty in patients with atrial fibrillation and impact on anticoagulant dosing: an ETNA-AF-Europe sub-analysis.
    Diemberger I; Fumagalli S; Mazzone AM; Bakhai A; Reimitz PE; Pecen L; Manu MC; Gordillo de Souza JA; Kirchhof P; De Caterina R
    Europace; 2022 Oct; 24(9):1404-1411. PubMed ID: 35512229
    [TBL] [Abstract][Full Text] [Related]  

  • 107. PrevAleNce and Associated factors of inappropriaTe dosing of direct Oral anticoaguLants In pAtients with Atrial Fibrillation: the ANATOLIA-AF Study.
    Kocabaş U; Ergin I; Yavuz V; Murat S; Özdemir I; Genç Ö; Altın C; Tüner H; Meriç BK; Çoner A; Yüce Eİ; Boyraz B; Aslan O; Dal A; Şen T; İbişoğlu E; Erdoğan A; Özgeyik M; Demir M; Bilgel ZG; Şengör BG; Urgun ÖD; Doğduş M; Tekin DDN; Çakal S; Çayırlı S; Güler A; Karabulut D; Dalgıç O; Uzman O; Murat B; Şahin Ş; Karabulut U; Kıvrak T; Coşgun MS; Özyurtlu F; Kaplan M; Özçalık E;
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):581-599. PubMed ID: 36527566
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Prevalence, risk factors, and prediction of inappropriate use of non-vitamin K antagonist oral anticoagulants in elderly Chinese patients with atrial fibrillation: A study protocol.
    Zhao SJ; Chen BY; Hong XJ; Liu YP; Cai HX; Du S; Gu ZC; Ma PZ
    Front Cardiovasc Med; 2022; 9():951695. PubMed ID: 36093129
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Prevalence and predictors of inappropriate dosing of direct oral anticoagulants.
    Ko HTK; Pham J; Anpalahan M
    Intern Med J; 2023 Oct; 53(10):1790-1795. PubMed ID: 36448650
    [TBL] [Abstract][Full Text] [Related]  

  • 110. The challenge of managing multimorbid atrial fibrillation: a pan-European European Heart Rhythm Association (EHRA) member survey of current management practices and clinical priorities.
    Lee G; Baker E; Collins R; Merino JL; Desteghe L; Heidbuchel H
    Europace; 2022 Dec; 24(12):2004-2014. PubMed ID: 36036694
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Multimorbidity management in atrial fibrillation: The Polish perspective in the EHRA-PATHS study.
    Lee GA; Farkowski MM; Baker E; Sterliński M; van Gelder IC; Dąbrowski R; Desteghe L; Szumowski Ł; Merino JL; Collins R; Rienstra M; Heidbuchel H
    Kardiol Pol; 2023; 81(6):580-586. PubMed ID: 36929302
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Correction to: Prevalence and Associated Factors of Inappropriate Dosing of Direct Oral Anticoagulants In Patients With Atrial Fibrillation: The ANATOLIA-AF Study.
    Kocabaş U; Ergin I; Yavuz V; Murat S; Özdemir I; Genç Ö; Altın C; Tüner H; Meriç BK; Çoner A; Yüce Eİ; Boyraz B; Aslan O; Dal A; Şen T; İbişoğlu E; Erdoğan A; Özgeyik M; Demir M; Bilgel ZG; Şengör BG; Urgun ÖD; Doğduş M; Tekin DDN; Çakal S; Çayırlı S; Güler A; Karabulut D; Dalgıç O; Uzman O; Murat B; Şahin Ş; Karabulut U; Kıvrak T; Coşgun MS; Özyurtlu F; Kaplan M; Özçalık E;
    Cardiovasc Drugs Ther; 2024 Jun; 38(3):601-603. PubMed ID: 36656413
    [No Abstract]   [Full Text] [Related]  

  • 113. Exploring the pharmacists' role in optimising antithrombotic therapy in primary care: a qualitative study.
    van Paassen JG; Tan JP; Deneer VHM; Bouvy ML
    BMJ Open; 2024 Mar; 14(3):e079018. PubMed ID: 38508648
    [TBL] [Abstract][Full Text] [Related]  

  • 114. A cross-sectional study of appropriateness evaluation of anticoagulation therapy for inpatients with nonvalvular atrial fibrillation.
    Zheng XY; Feng GW; Guo J; Xie F; Li X; Zhang MZ; Zhang XF; Wu XF; Ding YJ
    Front Pharmacol; 2023; 14():1286559. PubMed ID: 38116077
    [No Abstract]   [Full Text] [Related]  

  • 115. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Haeusler KG; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Eur Heart J; 2018 Apr; 39(16):1330-1393. PubMed ID: 29562325
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: Executive summary.
    Heidbuchel H; Verhamme P; Alings M; Antz M; Diener HC; Hacke W; Oldgren J; Sinnaeve P; Camm AJ; Kirchhof P;
    Eur Heart J; 2017 Jul; 38(27):2137-2149. PubMed ID: 27282612
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Outcomes and drivers of inappropriate dosing of non-vitamin K antagonist oral anticoagulants (NOACs) in patients with atrial fibrillation: a systematic review and meta-analysis.
    Caso V; de Groot JR; Sanmartin Fernandez M; Segura T; Blomström-Lundqvist C; Hargroves D; Antoniou S; Williams H; Worsley A; Harris J; Caleyachetty A; Vardar B; Field P; Ruff CT
    Heart; 2023 Jan; 109(3):178-185. PubMed ID: 36316100
    [TBL] [Abstract][Full Text] [Related]  

  • 118. The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.
    Steffel J; Verhamme P; Potpara TS; Albaladejo P; Antz M; Desteghe L; Georg Haeusler K; Oldgren J; Reinecke H; Roldan-Schilling V; Rowell N; Sinnaeve P; Collins R; Camm AJ; Heidbüchel H;
    Europace; 2018 Aug; 20(8):1231-1242. PubMed ID: 29562331
    [TBL] [Abstract][Full Text] [Related]  

  • 119. Appropriateness of Non-vitamin K Antagonist Oral Anticoagulants Dosing According to Different Prescription Guides Used in Belgian Ambulatory Care.
    Delesie M; Ballet A; Hillegeer C; Desteghe L; Dendale P; Heidbuchel H
    Clin Drug Investig; 2022 Sep; 42(9):775-786. PubMed ID: 35986867
    [TBL] [Abstract][Full Text] [Related]  

  • 120.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.